Postoperative High-Dose Intravenous Iron Sucrose with Low Dose Erythropoietin Therapy after Total Hip Replacement
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Erythropoietin combined with parenteral iron sucrose therapy is an alternative to blood transfusion in anemic patients. It was shown to be effective in surgical patients in several previous studies when used in conjunction with other methods. However, there are no guidelines about safety limits in dosage amounts or intervals. In this study, we report a case of significant postoperative hemorrhage managed with high dose parenteral iron sucrose, low dose erythropoietin, vitamin B12, vitamin C, and folic acid. An 80-year-old female patient presented for severe anemia after a total hip arthroplasty and refused an allogenic blood transfusion as treatment. The preoperative hemoglobin of 12.2 g/dL decreased to 5.3 g/dL postoperatively. She received the aforementioned combination of iron sucrose, erythropoietin, and vitamins. A total of 1,500 mg of intravenous iron sucrose was given postoperatively for 6 consecutive days. Erythropoietin was also administered at 2,000 IU every other day for a total of 12,000 IU. The patient was discharged in good condition on the twelfth postoperative day with a hemoglobin of 8.5 g/dL. Her hemoglobin was at 11.2 g/dL on the twentieth postoperative day. (Korean J Intern Med 2010;25:454-457)
Abstract
Erythropoietin combined with parenteral iron sucrose therapy is an alternative to blood transfusion in anemic patients. It was shown to be effective in surgical patients in several previous studies when used in conjunction with other methods. However, there are no guidelines about safety limits in dosage amounts or intervals. In this study, we report a case of significant postoperative hemorrhage managed with high dose parenteral iron sucrose, low dose erythropoietin, vitamin B12, vitamin C, and folic acid. An 80-year-old female patient presented for severe anemia after a total hip arthroplasty and refused an allogenic blood transfusion as treatment. The preoperative hemoglobin of 12.2 g/dL decreased to 5.3 g/dL postoperatively. She received the aforementioned combination of iron sucrose, erythropoietin, and vitamins. A total of 1,500 mg of intravenous iron sucrose was given postoperatively for 6 consecutive days. Erythropoietin was also administered at 2,000 IU every other day for a total of 12,000 IU. The patient was discharged in good condition on the twelfth postoperative day with a hemoglobin of 8.5 g/dL. Her hemoglobin was at 11.2 g/dL on the twentieth postoperative day. (Korean J Intern Med 2010;25:454-457)
참고문헌 (20)
- Klein HG, "Allogeneic transfusion risks in the surgical patient", Am J Surg, 170(6A), pp.21S~26S (1995)
- Rosencher N, "Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe", Transfusion, 43, pp.459~469 (2003)
- Cuenca J, "Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery", Transfusion, 46, pp.1112~1119 (2006)
- García-Erce JA, "Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery", Transfus Med, 16, pp.335~341 (2006)
- Billote DB, "A prospective, randomized study of preoperative autologous donation for hip replacement surgery", Bone Joint Surg Am, 84, pp.1299~1304 (2002)
- Atabek U, "Erythropoetin accelerates hematocrit recovery in post-surgical anemia", Am Surg, 61, pp.74~77 (1995)
- Schwenk MH, "Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney disease", Clin Nephrol, 62, pp.116~120 (2004)
- Aronoff GR, "Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens", Kidney Int, 66, pp.1193~1198 (2004)
- Fletes R, "Suspected iron dextran-related adverse drug events in hemodialysis patients", Am J Kidney Dis, 37, pp.743~749 (2001)
- Macdougall IC, "Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections", Am J Kidney Dis, 46, pp.283~289 (2005)
- Goodnough LT, "Erythropoietin therapy", N Engl J Med, 336, pp.933~938 (1997)
- Ganz T, "Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation", Blood, 102, pp.783~788 (2003)
- Ganz T, "Hepcidin: a regulator of intestinal iron absorption and iron recycling by macrophages", Best Pract Res Clin Haematol, 18, pp.171~182 (2005)
- Brines M, "Discovering erythropoietin's extrahematopoietic functions: biology and clinical promise", Kidney Int, 70, pp.246~250 (2006)
- Corwin HL, "Efficacy and safety of epoetin alfa in critically ill patients", N Engl J Med, 357, pp.965~976 (2007)
- Zarychanski R, "Erythropoietin-receptor agonists in critically ill patients: a metaanalysis of randomized controlled trials", CMAJ, 177, pp.725~734 (2007)
- Fliser D, "Erythropoietin and treatment of non-anemic conditions: cardiovascular protection", Semin Hematol, 44, pp.212~217 (2007)
- Sturm B, "Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron", Kidney Int, 67, pp.1161~1170 (2005)
- Shiga T, "Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials", Anesth Analg, 101, pp.1602~1607 (2005)
- Kourtzis N, "Blood saving protocol in elective total knee arthroplasty", Am J Surg, 187, pp.261~267 (2004)